04.05.2023 SARTORIUS AG  DE0007165607

EQS-News: SARTORIUS AG: Sartorius announces CFO transition


EQS-News: SARTORIUS AG / Key word(s): Personnel
SARTORIUS AG: Sartorius announces CFO transition (news with additional features)

04.05.2023 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Göttingen, May 4, 2023

Sartorius announces CFO transition
  • Rainer Lehmann to step down as Chief Financial Officer later this year; Sartorius commences search process

Sartorius’ Chief Financial Officer Rainer Lehmann will step down from his position by the end of October 2023 to pursue a new opportunity outside the company. The Supervisory Board of Sartorius AG has initiated a search process to identify a successor to Rainer Lehmann and to ensure a seamless transition.

“Rainer Lehmann has elevated our finance organization and contributed significantly to the strategic and operational development of Sartorius,” said Dr. Lothar Kappich, Chairman of the Supervisory Board of Sartorius AG. “His many contributions include managing our financing activities to support our portfolio strategy and capacity expansions as well as significantly expanding the company´s IT and digital capabilities. We are truly grateful for the strong foundation he built and wish him all the best personally and for his next professional step.”

Rainer Lehmann has been with Sartorius since 1999 with the exception for the years 2004 to 2006 and was appointed CFO in March 2017. Prior to that he served as the CFO of the company’s Americas business. In his current function Lehmann is responsible for Finance & Controlling, IT, Business Process and Data Management, Corporate Purchasing, E-Business Platforms, and Post-Merger Integration.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events.

A profile of Sartorius
The Sartorius Group is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly and economically. The company based in Goettingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies. In fiscal 2022, the company generated sales revenue of around 4.2 billion euros. At the end of 2022, around 16,000 employees were working for customers around the globe.

Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686
[email protected]

Follow Sartorius on Twitter and LinkedIn.

Additional features:

File: Rainer Lehmann (Copyright: Sartorius)

04.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Otto-Brenner-Straße 20
37079 Göttingen
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: [email protected]
Internet: www.sartorius.com
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1623967

End of News EQS News Service

1623967  04.05.2023 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.404,57 1.566,03 1.826,97 2.335,66 3.449,22 4.174,70 3.395,70
EBITDA1,2 353,20 405,00 495,80 636,70 1.134,26 1.410,40 962,70
EBITDA-Marge3 25,15 25,86 27,14 27,26 32,89 33,78
EBIT1,4 219,36 298,61 335,66 456,11 903,16 1.070,00 503,90
EBIT-Marge5 15,62 19,07 18,37 19,53 26,18 25,63 14,84
Jahresüberschuss1 159,33 197,48 218,74 299,56 426,98 655,40 290,00
Netto-Marge6 11,34 12,61 11,97 12,83 12,38 15,70 8,54
Cashflow1,7 206,51 244,52 377,19 511,53 865,81 734,20 853,60
Ergebnis je Aktie8 2,11 2,56 3,06 4,37 8,08 9,57 4,94
Dividende8 0,51 0,61 0,35 0,70 1,25 1,43 0,45
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: -

Sartorius ST
WKN Kurs in € Einschätzung Börsenwert in Mio. €
716560 275,500 Halten 23.482,37
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
45,16 39,18 1,15 63,35
10,23 24,17 6,92 26,55
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
1,43 0,73 0,26 28.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
18.04.2024 19.07.2024 17.10.2024 16.02.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,43% 6,92% 3,96% -13,91%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SARTORIUS AG  ISIN: DE0007165607 können Sie bei EQS abrufen

Medtech , 716560 , SRT , XETR:SRT